TABLE 3.

Inhibitory activity of lipopeptide fusion inhibitors on T-20-resistant HIV-1 mutants and HIV-2 and SIV isolates^a

Virus	Mean IC50 ± SD (nM) for:
	T-20	LP-80	LP-83	LP-86	LP-93	LP-94	LP-95	C34-Chol
T-20 sensitive
NL4-3D36G	8.564 ± 1.045	0.003 ± 0.001	0.002 ± 0	0.003 ± 0	0.006 ± 0.001	0.004 ± 0.002	0.067 ± 0.026	0.012 ± 0.001
T-20 resistant
NL4-3WT	169.333 ± 2.559	0.007 ± 0.002	0.002 ± 0.001	0.003 ± 0	0.012 ± 0.001	0.006 ± 0	0.39 ± 0.016	0.029 ± 0.001
NL4-3I37T	1,256.333 ± 54.501	0.121 ± 0.022	0.002 ± 0	0.004 ± 0	0.019 ± 0.002	0.004 ± 0	3.541 ± 0.307	0.042 ± 0.005
NL4-3V38A	2,268 ± 41.581	0.551 ± 0.071	0.008 ± 0.001	0.028 ± 0.008	0.045 ± 0.004	0.061 ± 0.001	9.432 ± 1.999	0.034 ± 0.014
NL4-3V38M	1,056 ± 44.643	0.262 ± 0.014	0.004 ± 0	0.014 ± 0.002	0.024 ± 0.003	0.031 ± 0.007	8.362 ± 3.532	0.044 ± 0.018
NL4-3Q40H	1,232.333 ± 97.992	0.325 ± 0.048	0.004 ± 0	0.011 ± 0.002	0.117 ± 0.024	0.018 ± 0.007	41.599 ± 1.56	0.038 ± 0.007
NL4-3N43K	794.667 ± 102.762	0.535 ± 0.028	0.009 ± 0.001	0.023 ± 0.004	0.267 ± 0.005	0.196 ± 0.007	57.802 ± 3.762	0.039 ± 0.006
NL4-3G36S/V38M	317.333 ± 18.728	0.209 ± 0.008	0.005 ± 0	0.012 ± 0.001	0.012 ± 0.003	0.0267 ± 0.003	3.828 ± 0.172	0.06 ± 0.014
NL4-3I37T/N43k	7,901± 1,091.948	4.006 ± 0.367	0.041 ± 0.004	0.124 ± 0.011	2.17 ± 0.135	2.295 ± 0.456	408.556 ± 12.919	0.047 ± 0.015
NL4-3V38A/N42T	6,260.333 ± 121.467	3.523 ± 0.195	0.034 ± 0.003	0.17 ± 0.046	0.34 ± 0.027	0.243 ± 0.059	82.514 ± 3.259	0.034 ± 0.003
HIV-2/SIV
HIV-2ROD	341.508 ± 130.145	0.288 ± 0.103	0.032 ± 0.005	0.026 ± 0.004	3.514 ± 0.907	0.019 ± 0.006	13.512 ± 1.881	0.929 ± 0.033
HIV-2ST	630.633 ± 84.581	0.299 ± 0.081	0.02 ± 0.008	0.014 ± 0.007	1.244 ± 0.079	0.027 ± 0.006	2.857 ± 0.541	0.53 ± 0.028
SIV239	534.33 ± 83.53	0.034 ± 0.002	0.004 ± 0	0.005 ± 0.001	0.013 ± 0.048	0.018 ± 0.002	0.862 ± 0.069	0.078 ± 0.009
SIVPBJ	915.516 ± 104.294	0.155 ± 0.06	0.006 ± 0.001	0.006 ± 0.002	0.773 ± 0.036	0.011 ± 0.002	0.556 ± 0.08	1.605 ± 0.421

^aThe assay was performed in triplicates and repeated three times.